缩宫素注射液致神经精神症状分析  

Neuropsychiatric Symptoms Induced by Oxytocin Injection

作　　者：白峻松 曹建英[2] 李佳 BAI Junsong;CAO Jianying;Li Jia(School of Health Management,Southern Medical University,Guangzhou Guangdong 510515,China;Department of Pharmacy,Weifang Maternal and Child Health Hospital,Weifang Shandong 261011,China;Weifang Adverse Drug Reaction Monitoring Center,Weifang Shandong 261061,China)

机构地区：[1]南方医科大学卫生管理学院,广东广州510515 [2]潍坊市妇幼保健院药剂科,山东潍坊261011 [3]潍坊市药品不良反应监测中心,山东潍坊261061

出　　处：《中国药物警戒》2021年第2期170-173,193,共5页Chinese Journal of Pharmacovigilance

摘　　要：目的分析缩宫素注射液致神经精神症状的用药风险,为临床合理用药提供参考。方法对2018~2019年山东省药品不良反应监测数据库及2013~2017年潍坊地区合计收到缩宫素注射液可疑药品不良反应(ADR)481例相关资料进行分析。结果监测数据和国内外文献显示,神经精神症状作为新的或(和)严重不良反应为缩宫素注射液较为突出的风险。结论加强缩宫素注射液的安全性监测及风险控制,及时完善产品说明书,促进临床安全合理用药。Objective To analyze the risk of neuropsychiatric symptoms induced by oxytocin injection.Methods A total of 481 cases of suspected ADRs caused by oxytocin injection collected by the ADR monitoring database of Shandong Province between 2018 and 2019 and by Weifang between 2013 and 2017 were analyzed.Results Monitoring data,domestic and foreign literature showed that neuropsychiatric symptoms were a new risk of serious adverse reactions induced by oxytocin injection.Conclusion The safety monitoring and risk control of oxytocin injection should be strengthened,and the product specifications should be updated quickly to promote the safe and rational use of drugs in clinical practice.

关 键 词：缩宫素注射液 神经精神症状 药品不良反应 

分 类 号：R984[医药卫生—药品]